the development and
manufacture of off-the-shelf,
universally implantable,

human tissues

The Humacyte Human Acellular VesselTM (HAVTM)

is a regenerative vascular conduit currently in various stages of clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. We believe our platform technology also has the potential to create solutions for complex organ disease, including bioengineered replacement tissues and  organs for coronary artery bypass grafts, pediatric heart sugery, and the treatment of Type 1 diabetes.

Innovation at
commercial scale

Humacyte, Inc. (Nasdaq: HUMA) has developed a disruptive biotechnology platform to deliver universally implantable, bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. Located in Durham, N.C., the company was founded in 2004 by Laura Niklason, MD, Ph.D., a world leader in tissue engineering and the Chief Executive Officer of Humacyte, along with Drs. Juliana Blum and Shannon Dahl.
Scroll to Top